When sorting through a heap of antibody candidates from a library, thermal stability and aggregation data help to separate the good from the bad and the ugly. Twist Biopharma, a division of Twist Bioscience, uses its proprietary DNA writing technology
to create large diverse oligo pools (upwards of 106) to develop a range of antibody phage display libraries. These libraries are either broadly applicable to any target or focused on a specific class of tough targets, e.g. GPCRs.
Screening Twist’s libraries often discovers a large panel of antibodies to each target, which can be further sorted based on biophysical performance.
In this webinar, Twist Biopharma will show how Uncle fits into their workflow to get an early read on stability, when sample volumes are small, to screen for the best candidates for development. Utilizing this data, they will show how they can
winnow their lead candidates down to a smaller number of top candidates to pursue further.
- Learn about Uncle’s unique combination of biophysical screening techniques for conformational and colloidal stability
- See the advantages of generating phage display libraries from large oligo pools
- Understand Twist Biopharma’s capabilities to generate diverse libraries and identify new antibody candidates
- See how Twist Biopharma’s workflows screen and refine libraries down to strongly binding, stable lead candidates
Aaron K. Sato, Ph.D.
Twist Biopharma, a division of Twist Bioscience
Aaron is a proven biologics leader adept at managing teams to discover and develop novel first-in-class antibody therapeutics. Prior to Twist Bioscience, he served as Chief Scientific Officer of LakePharma, leading the California Antibody Center,
which discovers novel antibody therapeutics for its clients. Prior to LakePharma, he oversaw all discovery research functions both as Vice President of Protein Sciences at Surrozen, and previously, as Vice President of Research at Sutro Biopharma,
Inc. He also served as Senior Director of Antibody Engineering at OncoMed Pharmaceuticals, where he was responsible for human antibody lead discovery and he served as project team leader on several key antibody projects through IND filing.
Before OncoMed, Aaron held positions of increasing responsibility at Dyax Corp., most recently as Senior Director of Lead Discovery, leading antibody, peptide, and small protein discovery using their proprietary phage display technology. He
earned his Ph.D. from the Massachusetts Institute of Technology where he studied MHC class II structure-function relationships. He is an author of over 30 peer reviewed papers and 40 issued patents in the antibody space.
Kevin Lance, Ph.D.
Kevin Lance is the Marketing Manager covering Uncle at Unchained Labs. He has published works and secured patents in the fields of sustained antibody delivery and nanotechnology, and has worked as a consultant to advance the development of biologics
for several major biopharmaceutical companies. He earned his Ph.D. in Bioengineering from the joint UC Berkeley – UCSF Bioengineering Graduate Program.
Cost: No Cost!